Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:anticoagulant
factor Xa inhibitor |
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA 2012 |
| gptkbp:ATCCode |
B01AF02
|
| gptkbp:bioavailability |
~50%
|
| gptkbp:brand |
gptkb:Eliquis
|
| gptkbp:CASNumber |
503612-47-3
|
| gptkbp:contraindication |
active pathological bleeding
severe hepatic impairment |
| gptkbp:developedBy |
gptkb:Pfizer
gptkb:Bristol-Myers_Squibb |
| gptkbp:eliminationHalfLife |
~12 hours
|
| gptkbp:excretion |
urine
feces |
| gptkbp:hasMolecularFormula |
C25H25N5O4
|
| https://www.w3.org/2000/01/rdf-schema#label |
apixaban
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits factor Xa
|
| gptkbp:metabolism |
liver
|
| gptkbp:molecularWeight |
459.5 g/mol
|
| gptkbp:pregnancyCategory |
B (Australia)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:anemia
nausea bleeding |
| gptkbp:usedFor |
prevention of stroke in atrial fibrillation
treatment of deep vein thrombosis treatment of pulmonary embolism prevention of recurrent DVT and PE |
| gptkbp:bfsParent |
gptkb:CYP3A4
|
| gptkbp:bfsLayer |
5
|